The story of Viagra, and its developer copyright, presents a challenging case study for investors. At first a blockbuster drug, yielding billions in sales , its patent expiration created a flood of lower-priced alternatives , significantly diminishing its position . While specific pharmaceutical companies may attempt to capitalize on related treatm